{{Rsnum
|rsid=2661319
|Gene=RGS4
|Chromosome=1
|position=163069987
|Orientation=minus
|GMAF=0.4293
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=RGS4
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 29.5 | 52.7 | 17.9
| HCB | 27.9 | 48.5 | 23.5
| JPT | 36.0 | 50.5 | 13.5
| YRI | 63.3 | 31.3 | 5.4
| ASW | 54.4 | 40.4 | 5.3
| CHB | 27.9 | 48.5 | 23.5
| CHD | 26.6 | 41.3 | 32.1
| GIH | 42.0 | 45.0 | 13.0
| LWK | 65.1 | 31.2 | 3.7
| MEX | 25.0 | 46.4 | 28.6
| MKK | 60.0 | 32.9 | 7.1
| TSI | 35.0 | 47.0 | 18.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=18804346
|Title=Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia
|OA=1
}}

{{PharmGKB
|RSID=rs2661319
|Name_s=
|Gene_s=RGS4
|Feature=
|Evidence=PubMed ID:18204343
|Annotation=Results from a study in patients with acutely exacerbated schizophrenia suggest that this variant in the RGS4 gene influences clinical manifestations of schizophrenia as well as the treatment response to risperidone.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162355847
}}

{{PMID Auto
|PMID=20414142
|Title=Association study between RGS4 and bipolar disorder in the Chinese Han population
}}

{{PharmGKB
|RSID=rs2661319
|Name_s=
|Gene_s=RGS4
|Feature=
|Evidence=PubMed ID:17588543; PubMed ID:18204343
|Annotation=This variant is associated with differential antipsychotic treatment response in individuals of african descent and chinese descent.
|Drugs=perphenazine; quetiapine; risperidone; ziprasidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA161889383
}}
{{PMID Auto
|PMID=19282471
|Title=RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample
|OA=1
}}

{{PMID|16905560}} RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity.

{{PMID|17092693}} RGS4 is not a susceptibility gene for schizophrenia in Japanese: association study in a large case-control population.

{{PMID|18262772|OA=1
}} Association of RGS2 and RGS5 variants with schizophrenia symptom severity.

{{PMID|18834502|OA=1
}} Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level.

{{PMID|19911060|OA=1
}} Persistence criteria for susceptibility genes for schizophrenia: a discussion from an evolutionary viewpoint.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2661319
|overall_frequency_n=51
|overall_frequency_d=128
|overall_frequency=0.398438
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=49
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23684163
|Title=Analysis of CpG SNPs in 34 genes: Association test with suicide attempt in schizophrenia
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}